

## Checklist for Reporting Human Islet Preparations Used in Research

Adapted from Hart NJ, Powers AC (2018) Progress, challenges, and suggestions for using human islets to understand islet biology and human diabetes. *Diabetologia* <https://doi.org/10.1007/s00125-018-4772-2>.

<b>Manuscript DOI:</b> <a href="https://doi.org/10.2337/[insert manuscript submission number]">https://doi.org/10.2337/[insert manuscript submission number]</a> (Example, <a href="https://doi.org/10.2337/db18-1234">https://doi.org/10.2337/db18-1234</a> )	
<b>Title:</b> Obesity-induced <i>miR-455</i> upregulation promotes adaptive pancreatic $\beta$ -cell proliferation through the CPEB1/CDKN1B pathway	
<b>Author list:</b> Qianxing Hu <sup>#</sup> , Jinming Mu <sup>#</sup> , Yuhong Liu <sup>#</sup> , Yue Yang, Yue Liu, Yi Pan, Yanfeng Zhang, Ling Li, Dechen Liu, Jianqiu Chen <sup>*</sup> , Fangfang Zhang <sup>*</sup> , Liang Jin <sup>*</sup>	
<b>Corresponding author:</b> Liang Jin	<b>Email address:</b> ljstemcell@cpu.edu.cn

Islet preparation	1	2	3	4	5	6	7	8 <sup>a</sup>
<b>MANDATORY INFORMATION</b>								
Unique identifier	Ling wang	Xun Ma	Ling Yin	Chonglan Zhang	Hao Hu	Hua Xu		
Donor age (years)	42	38	46	39	32	49		
Donor sex (M/F)	M	M	M	F	F	F		

Donor BMI (kg/m <sup>2</sup> )	23.3	24.5	25.7	23.2	24.1	26.2		
Donor HbA <sub>1c</sub> or other measure of blood glucose control	9.36	5.64	4.72	8.93	5.63	5.32		
Origin/source of islets <sup>b</sup>	Tianjin First Central Hospital							
Islet isolation centre	Organ Transplant Center, Tianjin First Central Hospital, Nankai University, China	Organ Transplant Center, Tianjin First Central Hospital, Nankai University, China	Organ Transplant Center, Tianjin First Central Hospital, Nankai University, China	Organ Transplant Center, Tianjin First Central Hospital, Nankai University, China	Organ Transplant Center, Tianjin First Central Hospital, Nankai University, China	Organ Transplant Center, Tianjin First Central Hospital, Nankai University, China		
Donor history of diabetes? Yes/No	No	No	No	No	No	No		
<b>If Yes, complete the next two lines if this information is available</b>								
Diabetes duration (years)								
Glucose-lowering therapy at time of death <sup>c</sup>								

**RECOMMENDED INFORMATION**

Donor cause of death	cancer	hematencephalon	hematencephalon	cancer	hematencephalon	hematencephalon		
Warm ischaemia time (h)	0	0	0	0	0	0		
Cold ischaemia time (h)	About 5.5							
Estimated purity (%)	>80 %	>80 %	>80 %	>80 %	>80 %	>80 %		
Estimated viability (%)	>80 %	>80 %	>80 %	>80 %	>80 %	>80 %		
Total culture time (h) <sup>d</sup>	About 6 h							
Glucose-stimulated insulin secretion or other functional measurement <sup>e</sup>	Islets were mixed for qRT-PCR assays, Glucose-stimulated insulin secretion assays; KI-67 staining; EMSA assays and Chip assays;	Islets were mixed for qRT-PCR assays, Glucose-stimulated insulin secretion assays; KI-67 staining; EMSA assays and Chip assays;	Islets were mixed for qRT-PCR assays, Glucose-stimulated insulin secretion assays; KI-67 staining; EMSA assays and Chip assays;	Islets were mixed for qRT-PCR assays, Glucose-stimulated insulin secretion assays; KI-67 staining; EMSA assays and Chip assays;	Islets were mixed for qRT-PCR assays, Glucose-stimulated insulin secretion assays; KI-67 staining; EMSA assays and Chip assays;	Islets were mixed for qRT-PCR assays, Glucose-stimulated insulin secretion assays; KI-67 staining; EMSA assays and Chip assays;		
Handpicked to purity? Yes/No	Yes	Yes	Yes	Yes	Yes	Yes		
Additional notes								

<sup>a</sup>If you have used more than eight islet preparations, please complete additional forms as necessary

<sup>b</sup>For example, IIDP, ECIT, Alberta IsletCore

<sup>c</sup>Please specify the therapy/therapies

<sup>d</sup>Time of islet culture at the isolation centre, during shipment and at the receiving laboratory

<sup>e</sup>Please specify the test and the results